HUE036931T2 - Az interferon intramuszkuláris beadásakor jelentkezõ influenzaszerû tünetek csökkentésének módszere egy gyors titrálási dózisemelõ kezelés alkalmazásával - Google Patents

Az interferon intramuszkuláris beadásakor jelentkezõ influenzaszerû tünetek csökkentésének módszere egy gyors titrálási dózisemelõ kezelés alkalmazásával

Info

Publication number
HUE036931T2
HUE036931T2 HUE12719487A HUE12719487A HUE036931T2 HU E036931 T2 HUE036931 T2 HU E036931T2 HU E12719487 A HUE12719487 A HU E12719487A HU E12719487 A HUE12719487 A HU E12719487A HU E036931 T2 HUE036931 T2 HU E036931T2
Authority
HU
Hungary
Prior art keywords
flu
interferon
symptoms
reducing
intramuscular administration
Prior art date
Application number
HUE12719487A
Other languages
English (en)
Hungarian (hu)
Inventor
Aaron Deykin
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of HUE036931T2 publication Critical patent/HUE036931T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
HUE12719487A 2011-03-15 2012-03-15 Az interferon intramuszkuláris beadásakor jelentkezõ influenzaszerû tünetek csökkentésének módszere egy gyors titrálási dózisemelõ kezelés alkalmazásával HUE036931T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161452807P 2011-03-15 2011-03-15
US201161476930P 2011-04-19 2011-04-19

Publications (1)

Publication Number Publication Date
HUE036931T2 true HUE036931T2 (hu) 2018-08-28

Family

ID=46045072

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12719487A HUE036931T2 (hu) 2011-03-15 2012-03-15 Az interferon intramuszkuláris beadásakor jelentkezõ influenzaszerû tünetek csökkentésének módszere egy gyors titrálási dózisemelõ kezelés alkalmazásával

Country Status (25)

Country Link
US (6) US9198955B2 (enExample)
EP (1) EP2686002B1 (enExample)
JP (2) JP6279905B2 (enExample)
KR (1) KR102050339B1 (enExample)
CN (1) CN103702680A (enExample)
AU (1) AU2012229104B2 (enExample)
BR (1) BR112013023609A8 (enExample)
CA (1) CA2846786C (enExample)
CY (1) CY1120176T1 (enExample)
DK (1) DK2686002T3 (enExample)
EA (1) EA028448B1 (enExample)
ES (1) ES2666850T3 (enExample)
HR (1) HRP20180621T1 (enExample)
HU (1) HUE036931T2 (enExample)
IL (1) IL228425A (enExample)
LT (1) LT2686002T (enExample)
MX (1) MX359947B (enExample)
PL (1) PL2686002T3 (enExample)
PT (1) PT2686002T (enExample)
RS (1) RS57175B1 (enExample)
SG (1) SG193446A1 (enExample)
SI (1) SI2686002T1 (enExample)
SM (1) SMT201800221T1 (enExample)
WO (1) WO2012125809A1 (enExample)
ZA (1) ZA201306933B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012125809A1 (en) * 2011-03-15 2012-09-20 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
HK1226092A1 (zh) * 2014-01-09 2017-09-22 Kyushu University, National University Corporation 制备小胶质细胞的方法
WO2018056584A1 (ko) 2016-09-21 2018-03-29 삼성전자 주식회사 피부 상태 측정 방법 및 이를 위한 전자 장치
CN116391233A (zh) * 2020-09-30 2023-07-04 皇家飞利浦有限公司 用于执行剂量滴定的方法和系统

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
DE3273787D1 (en) 1981-02-04 1986-11-20 Japan Found Cancer Human interferon-beta gene
US4695543A (en) 1982-03-23 1987-09-22 Bristol-Myers Company Alpha Interferon GX-1
CA1302320C (en) 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
FI90990C (fi) 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5641656A (en) 1993-10-22 1997-06-24 University Of Connecticut Nucleic acids encoding avian interferon (IFN) proteins and recombinant methods using them
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
JP2001104482A (ja) * 1999-10-07 2001-04-17 Terumo Corp 2室型プレフィルドシリンジ
ES2712469T3 (es) * 2003-01-30 2019-05-13 Becton Dickinson Co Soporte con escudo de seguridad para un dispositivo de administración de fármaco
BRPI0510526A (pt) * 2004-06-01 2007-10-30 Ares Trading Sa formulações lìquidas estabilizadas de interferon
US20060089593A1 (en) * 2004-10-26 2006-04-27 Sergio Landau Needle-free injection device for individual users
EP1923085A1 (en) * 2006-11-17 2008-05-21 Sanofi-Aventis Deutschland GmbH Dosing and drive mechanism for drug delivery device
JP2010513309A (ja) * 2006-12-18 2010-04-30 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモン製剤
US9044378B2 (en) * 2007-05-31 2015-06-02 Safety Syringes, Inc. Anti-needle stick safety device or system for use with drugs requiring reconstitution
JP5549048B2 (ja) * 2007-08-16 2014-07-16 味の素株式会社 薬剤バイアルとプレフィルドシリンジの接続構造
WO2010148337A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
WO2012125809A1 (en) * 2011-03-15 2012-09-20 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen

Also Published As

Publication number Publication date
CY1120176T1 (el) 2018-12-12
MX2013010507A (es) 2014-04-30
US20220280610A1 (en) 2022-09-08
IL228425A (en) 2017-08-31
CN103702680A (zh) 2014-04-02
EP2686002B1 (en) 2018-01-24
SMT201800221T1 (it) 2018-07-17
RS57175B1 (sr) 2018-07-31
US20200046804A1 (en) 2020-02-13
KR102050339B1 (ko) 2019-11-29
SI2686002T1 (en) 2018-06-29
MX359947B (es) 2018-10-17
EA028448B1 (ru) 2017-11-30
WO2012125809A1 (en) 2012-09-20
NZ712273A (en) 2016-09-30
US9198955B2 (en) 2015-12-01
KR20140038383A (ko) 2014-03-28
BR112013023609A2 (pt) 2016-12-06
ZA201306933B (en) 2016-07-27
ES2666850T3 (es) 2018-05-08
US20250276042A1 (en) 2025-09-04
PT2686002T (pt) 2018-04-23
US10500254B2 (en) 2019-12-10
JP2014508174A (ja) 2014-04-03
JP6279905B2 (ja) 2018-02-14
US20120237479A1 (en) 2012-09-20
AU2012229104A1 (en) 2013-10-03
LT2686002T (lt) 2018-05-10
EA201301024A1 (ru) 2014-03-31
CA2846786C (en) 2022-05-17
EP2686002A1 (en) 2014-01-22
JP2018030847A (ja) 2018-03-01
BR112013023609A8 (pt) 2018-04-03
CA2846786A1 (en) 2012-09-20
AU2012229104B2 (en) 2017-03-16
HRP20180621T1 (hr) 2018-07-27
DK2686002T3 (en) 2018-04-30
PL2686002T3 (pl) 2018-10-31
SG193446A1 (en) 2013-10-30
NZ616536A (en) 2015-10-30
US20170360890A1 (en) 2017-12-21
IL228425A0 (en) 2013-12-31
US20160101157A1 (en) 2016-04-14
JP6522069B2 (ja) 2019-05-29

Similar Documents

Publication Publication Date Title
CY2019015I1 (el) Χρηση πυριτικου ζιρκονιου για τη θεραπεια της υπερκαλιαιμιας
IL232046A0 (en) Purine derivatives for the treatment of viral infections
EP2667915A4 (en) INJEKTOR
LT2701773T (lt) Injekcinio švirkšto dozės kreiptuvai
DK2726141T3 (da) Enhed til oral levering af terapeutiske forbindelser
IL227900A0 (en) Yeast-based treatment in chronic hepatitis B infection
CO7020866A2 (es) Péptidos terapéuticos
DK2707029T3 (da) Fremgangsmåder til at behandle eller forebygge kolesterolrelaterede sygdomme
HUE049152T2 (hu) Hosszantartó hatású GLP-1 peptidek alkalmazása
SMT201700029B (it) Inibitori del virus dell'epatite c
IL227789A0 (en) Hepatitis c virus inhibitors
EP2768517A4 (en) HEPATITIS C-VIRUS HEMMER
IL229331A0 (en) Inhibitors for the hepatitis c virus
EP2704744A4 (en) FACTOR B COMPONENT ANALOGUES AND USES THEREOF
EP2790472A4 (en) PLASMA GENERATOR
FR2984554B1 (fr) Bus logiciel
PT2790693T (pt) Administração de estatinas sublinguais
CO6880064A2 (es) Métodos terapéuticos
HUE036931T2 (hu) Az interferon intramuszkuláris beadásakor jelentkezõ influenzaszerû tünetek csökkentésének módszere egy gyors titrálási dózisemelõ kezelés alkalmazásával
KR101715175B9 (ko) Lvs의 좌표계를 보정하는 방법
PT2780003T (pt) Tratamento da insuficiência adrenal
FR2972921B1 (fr) Sucette orthodontique
IL228729A0 (en) Treatment regimens
EP2680869A4 (en) HOMEOPATHIC THERAPY PROCEDURES AND COMPOSITIONS
ME03589B (me) Terapeutski tretman